TD Cowen initiated coverage of Septerna (SEPN) with a Buy rating and no price target The company is applying its Native Complex platform to build a pipeline of oral small molecule G protein-coupled receptor drugs, the analyst tells investors in a research note. The firm sees “significant potential for stock appreciation” based on Septerna’s validated targets in sizable markets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEPN: